Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1091)	3/15/2002 11:11:47 AM
From: tuck	Read Replies (1) \| Respond to of 1784

>>FRANKLIN, Mass., March 15 /PRNewswire/ -- Cohesive Technologies Inc. announced today the publication of a universal method that details how its TurboFlow(TM) high throughput liquid chromatography (HTLC) eliminates the need for method development in drug discovery. The paper is entitled, ``Generic Method for On-Line Extraction of Drug Substances in the Presence of Biological Matrices by Turbulent Flow LC/MS'' and it appears in the March 15th issue of Rapid Communications in Mass Spectrometry (Vol. 16, Issue 5, pg. 421-426). ``The use of liquid chromatography and mass spectrometry (LC/MS) to quantify drugs in biological matrices have been well established over the last decade, due to its high sensitivity and selectivity,'' said Joseph Herman, Senior Analytical Chemist at Cephalon Inc. and the author of the paper. ``However, to truly take full advantage of the screening, a generic method is needed that eliminates the development of new methods for each new compound being screened. ``Such a method was developed at Cephalon that takes advantage of turbulent flow chromatography in conjunction with LC/MS/MS techniques for high throughput screening of drug candidates in the presence of biological matrices,'' added Herman. ``The method has been used to screen over 1,000 compounds thus far and has met our sensitivity and reproducibility criterion on over 99 percent of the compounds tested. ``The advantage of this method is that development time is no longer needed to investigate new drug candidates and little, if any, sample preparation time is required. It is no longer necessary to separate each component of a complex nature chromatographically prior to analysis. The result is increased productivity through higher sample throughput,'' stated Herman. Cohesive's TurboFlow - high throughput liquid chromatography - breaks through the bottleneck at the front end of the mass spectrometer process by dispensing of sample preparation and running the chromatographic separation in considerably less time. TurboFlow was introduced in 1996, based on discoveries made by Cohesive's Chairman and Chief Technology Officer, Hubert M. Quinn. Since then, TurboFlow systems have been adopted by numerous major pharmaceutical, biotechnology and clinical diagnostics companies to accelerate their drug discovery and development efforts. Cohesive Technologies Inc. develops, manufactures and markets novel liquid chromatography systems and chemistries for the pharmaceutical drug discovery and development marketplace. These products have made Cohesive the emerging world leader in high-throughput bioanalysis. Detailed information about Cohesive Technologies' products and technology can be found on its web site www.cohesivetech.com.<< Cheers, Tuck